相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The roles of microRNAs in the progression of castration-resistant prostate cancer
Satoko Kojima et al.
JOURNAL OF HUMAN GENETICS (2017)
The molecular underpinnings of prostate cancer: impacts on management and pathology practice
Daniel Nava Rodrigues et al.
JOURNAL OF PATHOLOGY (2017)
Exploitation of Castration-Resistant Prostate Cancer Transcription Factor Dependencies by the Novel BET Inhibitor ABBV-075
Emily J. Faivre et al.
MOLECULAR CANCER RESEARCH (2017)
Protein arginine methyltransferase 5 functions as an epigenetic activator of the androgen receptor to promote prostate cancer cell growth
X. Deng et al.
ONCOGENE (2017)
P110β Inhibition Reduces Histone H3K4 Di-Methylation in Prostate Cancer
Jun Pang et al.
PROSTATE (2017)
Histone demethylase lysine demethylase 5B in development and cancer
Mengjiao Han et al.
ONCOTARGET (2017)
Exploitation of EP300 and CREBBP Lysine Acetyltransferases by Cancer
Narsis Attar et al.
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2017)
Chemical probes targeting epigenetic proteins: Applications beyond oncology
Suzanne Ackloo et al.
EPIGENETICS (2017)
Global Burden of Urologic Cancers, 1990-2013
Geolani W. Dy et al.
EUROPEAN UROLOGY (2017)
Benzoisoquinolinediones as Potent and Selective Inhibitors of BRPF2 and TAF1/TAF1L Bromodomains
Lea Bouche et al.
JOURNAL OF MEDICINAL CHEMISTRY (2017)
Discovery of First-in-Class, Potent, and Orally Bioavailable Embryonic Ectoderm Development (EED) Inhibitor with Robust Anticancer Efficacy
Ying Huang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2017)
The importance of DNA methylation in prostate cancer development
Charles E. Massie et al.
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY (2017)
Synthetic essentiality of chromatin remodelling factor CHD1 in PTEN-deficient cancer
Di Zhao et al.
NATURE (2017)
An allosteric PRC2 inhibitor targeting the H3K27me3 binding pocket of EED
Wei Qi et al.
NATURE CHEMICAL BIOLOGY (2017)
The EED protein-protein interaction inhibitor A-395 inactivates the PRC2 complex
Yupeng He et al.
NATURE CHEMICAL BIOLOGY (2017)
MicroRNA therapeutics: towards a new era for the management of cancer and other diseases
Rajesha Rupaimoole et al.
NATURE REVIEWS DRUG DISCOVERY (2017)
C-Met/miR-130b axis as novel mechanism and biomarker for castration resistance state acquisition
A. Cannistraci et al.
ONCOGENE (2017)
MicroRNA-455-3p functions as a tumor suppressor by targeting eIF4E in prostate cancer
Yongxiang Zhao et al.
ONCOLOGY REPORTS (2017)
Targeted protein degradation by PROTACs
Taavi K. Neklesa et al.
PHARMACOLOGY & THERAPEUTICS (2017)
Recent scenario of micro RNA as diagnostic and prognostic biomarkers of prostate cancer
Kamla Kant Shukla et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2017)
Proteasome-associated deubiquitinase ubiquitin-specific protease 14 regulates prostate cancer proliferation by deubiquitinating and stabilizing androgen receptor
Yuning Liao et al.
CELL DEATH & DISEASE (2017)
Targeting Cancer Cells with BET Bromodomain Inhibitors
Yali Xu et al.
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2017)
Epigenomic Regulation of Androgen Receptor Signaling: Potential Role in Prostate Cancer Therapy
Vito Cucchiara et al.
CANCERS (2017)
Discovery and Molecular Basis of a Diverse Set of Polycomb Repressive Complex 2 Inhibitors Recognition by EED
Ling Li et al.
PLOS ONE (2017)
Epigenetic Modulation Using Small Molecules - Targeting Histone Acetyltransferases in Disease
Andre Richters et al.
CURRENT MEDICINAL CHEMISTRY (2017)
Prostate cancer heterogeneity: Discovering novel molecular targets for therapy
Chiara Ciccarese et al.
CANCER TREATMENT REVIEWS (2017)
Bromodomain protein 4 discriminates tissue-specific super-enhancers containing disease-specific susceptibility loci in prostate and breast cancer
Verena Zuber et al.
BMC GENOMICS (2017)
A Phase Separation Model for Transcriptional Control
Denes Hnisz et al.
CELL (2017)
SPOP Mutation Drives Prostate Tumorigenesis In Vivo through Coordinate Regulation of PI3K/mTOR and AR Signaling
Mirjam Blattner et al.
CANCER CELL (2017)
Transcriptional Addiction in Cancer
James E. Bradner et al.
CELL (2017)
Androgen Receptor Coactivators in Regulation of Growth and Differentiation in Prostate Cancer
Zoran Culig
JOURNAL OF CELLULAR PHYSIOLOGY (2016)
Discovery of a Chemical Tool Inhibitor Targeting the Bromodomains of TRIM24 and BRPF
James Bennett et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
Structure-Guided Design of IACS-9571, a Selective High-Affinity Dual TRIM24-BRPF1 Bromodomain Inhibitor
Wylie S. Palmer et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
HDAC inhibition impedes epithelial-mesenchymal plasticity and suppresses metastatic, castration-resistant prostate cancer
M. Ruscetti et al.
ONCOGENE (2016)
Targeting cancer using KAT inhibitors to mimic lethal knockouts
James A. L. Brown et al.
BIOCHEMICAL SOCIETY TRANSACTIONS (2016)
Modulation of p300/CBP Acetylation of Nucleosomes by Bromodomain Ligand I-CBP112
Beth E. Zucconi et al.
BIOCHEMISTRY (2016)
Immunotherapy for Prostate Cancer: False Promises or True Hope?
Brian T. Rekoske et al.
CANCER (2016)
TRIM24 Is an Oncogenic Transcriptional Activator in Prostate Cancer
Anna C. Groner et al.
CANCER CELL (2016)
Loss of CHD1 causes DNA repair defects and enhances prostate cancer therapeutic responsiveness
Vijayalakshmi Kari et al.
EMBO REPORTS (2016)
Phase I and II therapies targeting the androgen receptor for the treatment of castration resistant prostate cancer
Athanasios Dellis et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2016)
Targeting epigenetic regulators for cancer therapy: modulation of bromodomain proteins, methyltransferases, demethylases, and microRNAs
Kathy A. Gelato et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2016)
The Bromodomain and Extra-Terminal Domain (BET) Family: Functional Anatomy of BET Paralogous Proteins
Yasushi Taniguchi
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2016)
Reducible self-assembling cationic polypeptide-based micelles mediate co-delivery of doxorubicin and microRNA-34a for androgen-independent prostate cancer therapy
Chong Yao et al.
JOURNAL OF CONTROLLED RELEASE (2016)
BET Bromodomain Inhibitors Enhance Efficacy and Disrupt Resistance to AR Antagonists in the Treatment of Prostate Cancer
Irfan A. Asangani et al.
MOLECULAR CANCER RESEARCH (2016)
KAT8 Regulates Androgen Signaling in Prostate Cancer Cells
Ji-Young Kim et al.
MOLECULAR ENDOCRINOLOGY (2016)
Translational and clinical implications of the genetic landscape of prostate cancer
Daniel E. Spratt et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2016)
Drug discovery in advanced prostate cancer: translating biology into therapy
Timothy A. Yap et al.
NATURE REVIEWS DRUG DISCOVERY (2016)
Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer
C. C. Pritchard et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer
Kanak Raina et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
Novel and next-generation androgen receptor-directed therapies for prostate cancer: Beyond abiraterone and enzalutamide
Richard M. Bambury et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2016)
Combination effect of therapies targeting the PI3K-and AR-signaling pathways in prostate cancer
Shalini Singh Yadav et al.
ONCOTARGET (2016)
BET bromodomain-mediated interaction between ERG and BRD4 promotes prostate cancer cell invasion
Alexandra M. Blee et al.
ONCOTARGET (2016)
Cellular androgen content influences enzalutamide agonism of F877L mutant androgen receptor
Daniel J. Coleman et al.
ONCOTARGET (2016)
Genomic and epigenomic analysis of high-risk prostate cancer reveals changes in hydroxymethylation and TET1
Lien Spans et al.
ONCOTARGET (2016)
c-MYC drives histone demethylase PHF8 during neuroendocrine differentiation and in castration-resistant prostate cancer
Peterson Kariuki Maina et al.
ONCOTARGET (2016)
Targeting bet bromodomain proteins in solid tumors
Vaibhav Sahai et al.
ONCOTARGET (2016)
Oncogenic microRNA-4534 regulates PTEN pathway in prostate cancer
Hannah Nip et al.
ONCOTARGET (2016)
Epigenetic modulators as therapeutic targets in prostate cancer
Ines Graca et al.
CLINICAL EPIGENETICS (2016)
ERG signaling in prostate cancer is driven through PRMT5-dependent methylation of the Androgen Receptor
Zineb Mounir et al.
ELIFE (2016)
The HIF/PHF8/AR axis promotes prostate cancer progression
D. Tong et al.
ONCOGENESIS (2016)
MicroRNAs as Biomarkers for Diagnosis, Prognosis and Theranostics in Prostate Cancer
Gloria Bertoli et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2016)
Class I HDAC inhibitor mocetinostat induces apoptosis by activation of miR-31 expression and suppression of E2F6
Q. Zhang et al.
CELL DEATH DISCOVERY (2016)
The genomic evolution of human prostate cancer
T. Mitchell et al.
BRITISH JOURNAL OF CANCER (2015)
miR-124 and Androgen Receptor Signaling Inhibitors Repress Prostate Cancer Growth by Downregulating Androgen Receptor Splice Variants, EZH2, and Src
Xu-Bao Shi et al.
CANCER RESEARCH (2015)
Coordinate Loss of MAP3K7 and CHD1 Promotes Aggressive Prostate Cancer
Lindsey Ulkus Rodrigues et al.
CANCER RESEARCH (2015)
miR-145 suppress the androgen receptor in prostate cancer cells and correlates to prostate cancer prognosis
Olivia Larne et al.
CARCINOGENESIS (2015)
Overexpression of enhancer of zeste homolog 2 (EZH2) characterizes an aggressive subset of prostate cancers and predicts patient prognosis independently from pre- and postoperatively assessed clinicopathological parameters
Nathaniel Melling et al.
CARCINOGENESIS (2015)
Integrative Clinical Genomics of Advanced Prostate Cancer
Dan Robinson et al.
CELL (2015)
The Molecular Taxonomy of Primary Prostate Cancer
Adam Abeshouse et al.
CELL (2015)
The PRMT5 arginine methyltransferase: many roles in development, cancer and beyond
Nicole Stopa et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2015)
Phase I/II Study of Azacitidine, Docetaxel, and Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Therapy
Rakesh Singal et al.
CLINICAL GENITOURINARY CANCER (2015)
Implications of ubiquitin ligases in castration-resistant prostate cancer
Jianfei Qi et al.
CURRENT OPINION IN ONCOLOGY (2015)
A phase II study of the HDAC inhibitor SB939 in patients with castration resistant prostate cancer: NCIC clinical trials group study IND195
B. J. Eigl et al.
INVESTIGATIONAL NEW DRUGS (2015)
The Deubiquitinating Enzyme USP7 Regulates Androgen Receptor Activity by Modulating Its Binding to Chromatin
Shu-Ting Chen et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2015)
A SMYD3 Small-Molecule Inhibitor Impairing Cancer Cell Growth
Alessia Peserico et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2015)
The evolutionary history of lethal metastatic prostate cancer
Gunes Gundem et al.
NATURE (2015)
NAR Breakthrough Article Targeting chromatin binding regulation of constitutively active AR variants to overcome prostate cancer resistance to endocrine-based therapies
Siu Chiu Chan et al.
NUCLEIC ACIDS RESEARCH (2015)
Targeting BET bromodomains for cancer treatment
Marie Jung et al.
EPIGENOMICS (2015)
Microdissecting the role of microRNAs in the pathogenesis of prostate cancer
Shiekh Gazalla Ayub et al.
CANCER GENETICS (2015)
SMYD3 contributes to a more aggressive phenotype of prostate cancer and targets Cyclin D2 through H4K20me3
Filipa Quintela Vieira et al.
ONCOTARGET (2015)
NCL1, a highly selective lysine-specific demethylase 1 inhibitor, suppresses prostate cancer without adverse effect
Toshiki Etani et al.
ONCOTARGET (2015)
Global DNA hypomethylation in prostate cancer development and progression: a systematic review
R. Zelic et al.
PROSTATE CANCER AND PROSTATIC DISEASES (2015)
Histone deacetylase inhibitors in castration-resistant prostate cancer: molecular mechanism of action and recent clinical trials
Dharam Kaushik et al.
THERAPEUTIC ADVANCES IN UROLOGY (2015)
Demethylation of the miR-146a promoter by 5-Aza-2′-deoxycytidine correlates with delayed progression of castration-resistant prostate cancer
Xiaolu Wang et al.
BMC CANCER (2014)
DNA methylation status is more reliable than gene expression at detecting cancer in prostate biopsy
A. Paziewska et al.
BRITISH JOURNAL OF CANCER (2014)
BET bromodomain inhibitors-A novel epigenetic approach in castration-resistant prostate cancer
Sarah E. Lochrin et al.
CANCER BIOLOGY & THERAPY (2014)
Androgen Receptor Is the Key Transcriptional Mediator of the Tumor Suppressor SPOP in Prostate Cancer
Chuandong Geng et al.
CANCER RESEARCH (2014)
The convergence of DNA damage checkpoint pathways and androgen receptor signaling in prostate cancer
Huy Q. Ta et al.
ENDOCRINE-RELATED CANCER (2014)
A Role for WDR5 in Integrating Threonine 11 Phosphorylation to Lysine 4 Methylation on Histone H3 during Androgen Signaling and in Prostate Cancer
Ji-Young Kim et al.
MOLECULAR CELL (2014)
Coactivator MYST1 Regulates Nuclear Factor-κB and Androgen Receptor Functions During Proliferation of Prostate Cancer Cells
Anbalagan Jaganathan et al.
MOLECULAR ENDOCRINOLOGY (2014)
Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer
Irfan A. Asangani et al.
NATURE (2014)
Three-tiered role of the pioneer factor GATA2 in promoting androgen-dependent gene expression in prostate cancer
Dayong Wu et al.
NUCLEIC ACIDS RESEARCH (2014)
Novel Epigenetic Target Therapy for Prostate Cancer: A Preclinical Study
Ilaria Naldi et al.
PLOS ONE (2014)
An oncogenic super-enhancer formed through somatic mutation of a noncoding intergenic element
Marc R. Mansour et al.
SCIENCE (2014)
Ubiquitylome analysis identifies dysregulation of effector substrates in SPOP-mutant prostate cancer
Jean-Philippe P. Theurillat et al.
SCIENCE (2014)
Connections between TET proteins and aberrant DNA modification in cancer
Yun Huang et al.
TRENDS IN GENETICS (2014)
Epigenetic modifications in prostate cancer
Marjolaine Ngollo et al.
EPIGENOMICS (2014)
Intratumor DNA Methylation Heterogeneity Reflects Clonal Evolution in Aggressive Prostate Cancer
David Brocks et al.
CELL REPORTS (2014)
A phase 2 study of intravenous panobinostat in patients with castration-resistant prostate cancer
Dana E. Rathkopf et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2013)
Multifaceted role of EZH2 in breast and prostate tumorigenesis: Epigenetics and beyond
Gauri Deb et al.
EPIGENETICS (2013)
SMYD3 as an Oncogenic Driver in Prostate Cancer by Stimulation of Androgen Receptor Transcription
Cheng Liu et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2013)
The lysine specific demethylase-1 (LSD1/KDM1A) regulates VEGF-A expression in prostate cancer
Vasundhra Kashyap et al.
MOLECULAR ONCOLOGY (2013)
The lysine demethylase, KDM4B, is a key molecule in androgen receptor signalling and turnover
Kelly Coffey et al.
NUCLEIC ACIDS RESEARCH (2013)
Increased levels of DNA methyltransferases are associated with the tumorigenic capacity of prostate cancer cells
Giovanni Luca Gravina et al.
ONCOLOGY REPORTS (2013)
Panobinostat synergizes with zoledronic acid in prostate cancer and multiple myeloma models by increasing ROS and modulating mevalonate and p38-MAPK pathways
F. Bruzzese et al.
CELL DEATH & DISEASE (2013)
Inhibition of BET bromodomain proteins as a therapeutic approach in prostate cancer
Anastasia Wyce et al.
ONCOTARGET (2013)
EZH2, an epigenetic driver of prostate cancer
Yeqing Angela Yang et al.
PROTEIN & CELL (2013)
Transcription, DNA Damage and Beyond: The Roles of Histone Ubiquitination and Deubiquitination
Hai-Ning Du
CURRENT PROTEIN & PEPTIDE SCIENCE (2012)
The enigmatic role of H2Bub1 in cancer
Steven A. Johnsen
FEBS LETTERS (2012)
Selective Roles for cAMP Response Element-binding Protein Binding Protein and p300 Protein as Coregulators for Androgen-regulated Gene Expression in Advanced Prostate Cancer Cells
Irina Ianculescu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2012)
Regulation of the androgen receptor by post-translational modifications
Kelly Coffey et al.
JOURNAL OF ENDOCRINOLOGY (2012)
Discovery and Characterization of NK13650s, Naturally Occurring p300-Selective Histone Acetyltransferase Inhibitors
Shigehiro Tohyama et al.
JOURNAL OF ORGANIC CHEMISTRY (2012)
Histone demethylation and steroid receptor function in cancer
Antje Stratmann et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2012)
Histone H2B ubiquitin ligases RNF20 and RNF40 in androgen signaling and prostate cancer cell growth
Tiina Jaaskelainen et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2012)
The mutational landscape of lethal castration-resistant prostate cancer
Catherine S. Grasso et al.
NATURE (2012)
Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer
Christopher E. Barbieri et al.
NATURE GENETICS (2012)
Recurrent deletion of CHD1 in prostate cancer with relevance to cell invasiveness
S. Huang et al.
ONCOGENE (2012)
Systematic knockdown of epigenetic enzymes identifies a novel histone demethylase PHF8 overexpressed in prostate cancer with an impact on cell proliferation, migration and invasion
M. Bjorkman et al.
ONCOGENE (2012)
Lestaurtinib Inhibits Histone Phosphorylation and Androgen-Dependent Gene Expression in Prostate Cancer Cells
Jens Koehler et al.
PLOS ONE (2012)
Characterisation of a Tip60 Specific Inhibitor, NU9056, in Prostate Cancer
Kelly Coffey et al.
PLOS ONE (2012)
Alterations of global histone H4K20 methylation during prostate carcinogenesis
Turang E. Behbahani et al.
BMC UROLOGY (2012)
Histone ubiquitination and deubiquitination in transcription DNA damage response, and cancer
Jian Cao et al.
FRONTIERS IN ONCOLOGY (2012)
Androgen Receptor Gene Expression in Prostate Cancer Is Directly Suppressed by the Androgen Receptor Through Recruitment of Lysine-Specific Demethylase 1
Changmeng Cai et al.
CANCER CELL (2011)
Systematic Analysis of MicroRNAs Targeting the Androgen Receptor in Prostate Cancer Cells
Paivi Ostling et al.
CANCER RESEARCH (2011)
Hormonal Therapy Promotes Hormone-Resistant Phenotype by Increasing DNMT Activity and Expression in Prostate Cancer Models
Giovanni Luca Gravina et al.
ENDOCRINOLOGY (2011)
Androgen Receptor Signalling in Prostate Cancer: The Functional Consequences of Acetylation
Derek N. Lavery et al.
JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY (2011)
Pharmacologic disruption of Polycomb Repressive Complex 2 inhibits tumorigenicity and tumor progression in prostate cancer
Francesco Crea et al.
MOLECULAR CANCER (2011)
Inhibition of the Acetyltransferases p300 and CBP Reveals a Targetable Function for p300 in the Survival and Invasion Pathways of Prostate Cancer Cell Lines
Frederic R. Santer et al.
MOLECULAR CANCER THERAPEUTICS (2011)
USP10 deubiquitylates the histone variant H2A.Z and both are required for androgen receptor-mediated gene activation
Ryan Draker et al.
NUCLEIC ACIDS RESEARCH (2011)
EZH2 and cancer stem cells: fact or fiction?
Francesco Crea
EPIGENOMICS (2011)
Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer (CRPC)
L. R. Molife et al.
ANNALS OF ONCOLOGY (2010)
An Integrated Network of Androgen Receptor, Polycomb, and TMPRSS2-ERG Gene Fusions in Prostate Cancer Progression
Jindan Yu et al.
CANCER CELL (2010)
Global Levels of Specific Histone Modifications and an Epigenetic Gene Signature Predict Prostate Cancer Progression and Development
Tina Bianco-Miotto et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2010)
TAF1 Differentially Enhances Androgen Receptor Transcriptional Activity via Its N-Terminal Kinase and Ubiquitin-Activating and -Conjugating Domains
Peyman Tavassoli et al.
MOLECULAR ENDOCRINOLOGY (2010)
Tip60 Promotes Prostate Cancer Cell Proliferation by Translocation of Androgen Receptor into the Nucleus
Masaki Shiota et al.
PROSTATE (2010)
5-Azacitidine Restores and Amplifies the Bicalutamide Response on Preclinical Models of Androgen Receptor Expressing or Deficient Prostate Tumors
Giovanni Luca Gravina et al.
PROSTATE (2010)
Global Levels of Histone Modifications Predict Prostate Cancer Recurrence
Joerg Ellinger et al.
PROSTATE (2010)
Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive marker
P. N. Munster et al.
BRITISH JOURNAL OF CANCER (2009)
Vorinostat in Advanced Prostate Cancer Patients Progressing on Prior Chemotherapy (National Cancer Institute Trial 6862) Trial Results and Interleukin-6 Analysis: A study by the Department of Defense Prostate Cancer Clinical Trial Consortium and University of Chicago Phase 2 Consortium
Deborah Bradley et al.
CANCER (2009)
Androgen-Induced Coactivator ANCCA Mediates Specific Androgen Receptor Signaling in Prostate Cancer
June X. Zou et al.
CANCER RESEARCH (2009)
Histone Deacetylases Are Required for Androgen Receptor Function in Hormone-Sensitive and Castrate-Resistant Prostate Cancer
Derek S. Welsbie et al.
CANCER RESEARCH (2009)
Azacitidine improves antitumor effects of docetaxel and cisplatin in aggressive prostate cancer models
Claudio Festuccia et al.
ENDOCRINE-RELATED CANCER (2009)
Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy
W. Weichert et al.
BRITISH JOURNAL OF CANCER (2008)
Defining the molecular action of HDAC inhibitors and synergism with androgen deprivation in ERG-positive prostate cancer
Mari Bjorkman et al.
INTERNATIONAL JOURNAL OF CANCER (2008)
Androgen receptor acetylation sites differentially regulate gene control
Hortensia Faus et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2008)
Phase II trial of docetaxel with rapid androgen cycling for progressive noncastrate prostate cancer
Dana Rathkopf et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Genomic Androgen Receptor-Occupied Regions with Different Functions, Defined by Histone Acetylation, Coregulators and Transcriptional Capacity
Li Jia et al.
PLOS ONE (2008)
Circulating microRNAs as stable blood-based markers for cancer detection
Patrick S. Mitchell et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Antitumor activity of the histone deacetylase inhibitor MS-275 in prostate cancer models
David Z. Qian et al.
PROSTATE (2007)
Sirtuin 1 is required for antagonist-induced transcriptional repression of androgen-responsive genes by the androgen receptor
Yan Dai et al.
MOLECULAR ENDOCRINOLOGY (2007)
Cooperative demethylation by JMJD2C and LSD1 promotes androgen receptor-dependent gene expression
Melanie Wissmann et al.
NATURE CELL BIOLOGY (2007)
Androgen receptor coactivators lysine-specific histone demethylase 1 and four and a half LIM domain protein 2 predict risk of prostate cancer recurrence
Philip Kahl et al.
CANCER RESEARCH (2006)
Post-translational modifications of steroid receptors
H. Faus et al.
BIOMEDICINE & PHARMACOTHERAPY (2006)
Locus-wide chromatin remodeling and enhanced androgen receptor-mediated transcription in recurrent prostate tumor cells
Li Jia et al.
MOLECULAR AND CELLULAR BIOLOGY (2006)
Inhibition of DNA methyltransferase activity prevents tumorigenesis in a mouse model of prostate cancer
MT McCabe et al.
CANCER RESEARCH (2006)
The ubiquitin-specific protease USP10 modulates androgen receptor function
H Faus et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2005)
LSD1 demethylates repressive histone marks to promote androgen-receptor-dependent transcription
E Metzger et al.
NATURE (2005)
Global histone modification patterns predict risk of prostate cancer recurrence
DB Seligson et al.
NATURE (2005)
Regulation of androgen receptor and histone deacetylase 1 by Mdm2-mediated ubiquitylation
L Gaughan et al.
NUCLEIC ACIDS RESEARCH (2005)
Expression and function of androgen receptor coactivators in prostate cancer
Z Culig et al.
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY (2004)
Expression of Tip60, an androgen receptor coactivator, and its role in prostate cancer development
K Halkidou et al.
ONCOGENE (2003)
分享论文
